China opportunities

Due to an aging population in China, the risk of cardiovascular diseases (CVD) has significantly increased during the past two decades. Currently, China has the largest CVD patient population with an estimated 350 million patients. CVD also remains the leading cause of death at 48.0% and 43.6% in rural and urban areas, respectively. This is roughly twice the rate of cancer that ranges from 23% to 26%.

Despite the growing unmet need in CVD, pharmaceutical companies have not developed and launched novel treatments at the same rate as other disease areas in China. For example, there have been 54 new molecular entities (NME) approved for cancer between 2015-2020 compared to only 11 NMEs in cardiovascular conditions during the same time. JIXING is committed to bringing innovative cardiovascular therapeutics to China with the goal of improving and saving lives.

In China, there is a significant unmet medical need in ophthalmology, often associated with large patient segments. For dry eye disease alone, the patient population is estimated to be over 200 million. Dry eye disease and many other ophthalmic indications are age-related and with China’s aging population, these are important areas of focus.

Overall, new ophthalmic drug approvals in China have lagged compared to some other countries, with only eight new drugs approved in China between 2015-2020 versus 23 drugs in the U.S.. JIXING’s main goal is to develop and deliver innovative ophthalmic therapies to treat diseases with high unmet need in Greater China. As part of our commitment to ensure broad access to treatment for patients and improve diagnosis rates in ophthalmic conditions, we are planning to partner with government initiatives to increase eye examinations as part of the 14th 5-year National Health plan. The ambitious objective is to conduct annual fundus examinations among the broader general population and to meaningfully improve screening and diagnosis of many ophthalmic conditions.